Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

NCCN enhances widely used breast cancer guidelines with advanced digital features

Today, the National Comprehensive Cancer Network® (NCCN®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familial high-risk assessment, during Breast Cancer Awareness Month.

7 Oct 2025

Study identifies key molecular and clinical biomarkers for MASLD

The causal biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) and their clinical value remain unclear.

25 Sep 2025

Targeting TGF-β signaling as a strategy to treat liver fibrosis

Liver fibrosis, a pathological scarring process resulting from chronic liver injury, represents a significant global health burden due to its potential progression to cirrhosis and hepatocellular carcinoma.

25 Sep 2025

Coffee protects the liver by blocking inflammation and scarring, review finds

A new review in Biochemical Pharmacology synthesizes decades of research showing consistent links between regular coffee consumption and reduced risk of liver disease, including cirrhosis and liver cancer. Coffee’s bioactive compounds act on antioxidant, anti-inflammatory, antifibrotic, and metabolic pathways to slow liver damage progression.

21 Sep 2025

PANoptosis emerges as a promising strategy against liver cancer

Liver cancer, particularly hepatocellular carcinoma (HCC), remains one of the deadliest cancers, driven by high recurrence and resistance to therapy.

18 Sep 2025

Novel biotechnical vector integrates viral and synthetic features for targeted cancer therapy

Gene therapy offers the possibility of addressing cancer at its molecular roots by targeting disease-causing genes rather than relying solely on surgery, chemotherapy, or radiotherapy.

16 Sep 2025

Study identifies C1orf122 as prognostic marker in liver cancer

Primary liver cancer is the third leading cause of cancer-related deaths, of which hepatocellular carcinoma (HCC) accounts for approximately 90% of all liver cancer cases.

11 Sep 2025

Novel vascularized cancer-on-a-chip model reflects the microenvironment of liver tumors

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents.

3 Sep 2025

CHI3L1 emerges as a powerful biomarker for liver disease diagnosis and management

The identification of Chitinase-3-like protein 1 (CHI3L1) as a crucial biomarker in liver disease is revolutionizing how clinicians approach the diagnosis, monitoring, and treatment of various liver conditions.

22 Aug 2025

ATOX1 drives hepatocellular carcinoma progression through c-Myb and PI3K/AKT activation

Despite advancements in diagnostic and therapeutic strategies, hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality.

22 Aug 2025

Fucosylation emerges as a key player in digestive inflammatory diseases and cancers

Fucosylation, a crucial post-translational modification, has emerged as a significant factor influencing digestive inflammatory diseases and cancers.

18 Aug 2025

International commission calls for action against hepatocellular carcinoma

Liver cancer is the sixth most common cancer as well as the third highest cause of cancer-related mortality worldwide.

8 Aug 2025

Updated multidisciplinary European guidelines redefine MASLD diagnosis and treatment

The 2024 European clinical practice guidelines introduce a pivotal terminology shift, replacing NAFLD (non-alcoholic fatty liver disease) with MASLD (metabolic dysfunction-associated steatotic liver disease) and NASH with MASH (metabolic dysfunction-associated steatohepatitis).

7 Aug 2025

HOXB13 emerges as a context-dependent regulator in cancer biology

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a double-edged sword in human cancer.

5 Aug 2025

The vicious circle of aging and metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and aging are locked in a vicious circle: senescence of liver cells accelerates fat accumulation, inflammation and fibrosis, while chronic steatosis in turn hastens hepatic decline.

1 Aug 2025

Scarred liver tissue creates fertile ground for cancer development

Over 80% of hepatocellular carcinoma (HCC) – the third-leading cause of cancer deaths globally – emerges from advanced liver fibrosis or cirrhosis. A comprehensive review in Hepatology International synthesizes decades of research to reveal how scarred liver tissue becomes a breeding ground for cancer.

31 Jul 2025

Rising liver cancer rates highlight need for urgent action worldwide

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), suggests an analysis as part of The Lancet Commission on liver cancer.

29 Jul 2025

STRIDE immunotherapy sets new benchmark for survival in advanced liver cancer

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other localized treatments) has shown that one in five (19.6%) participants treated with STRIDE (Single Tremelimumab Regular Interval Durvalumab) a combination of two immunotherapies, remained alive after five years of follow-up versus one in 10 (9.4%) participants treated with sorafenib, a standard treatment for uHCC when the study was designed.

23 Jul 2025

Early-career physician-scientists receive major support from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

14 Jul 2025

UCLA study may help explain why certain liver tumors return after thermal ablation

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center may help explain why certain liver tumors return quickly after thermal ablation, a widely used minimally-invasive, image-guided technique that kills cancer cells by applying intense heat through a needle-like probe.

10 Jul 2025